Abstract:Introduction: Alzheimer's disease (AD) is characterized by the misfolding and aggregation of two major proteins: amyloid-beta (Aβ) and tau. Antibody-based PET radioligands are desirable due to their high specificity and affinity; however, antibody uptake in the brain is limited by the blood-brain barrier (BBB). Previously, we demonstrated that antibody transport across the BBB can be facilitated through interaction with the transferrin receptor (TfR), and the bispecific antibody-based PET ligands were capable of detecting Aβ aggregates via ex vivo imaging. Since tau accumulation in the brain is more closely correlated with neuronal death and cognition, we report here our strategies to prepare four F-18-labeled specifically engineered bispecific antibody probes for the selective detection of tau and Aβ aggregates to evaluate their feasibility and specificity, particularly for in vivo PET imaging. Methods: We first created and evaluated (via both in vitro and ex vivo studies) four specifically engineered bispecific antibodies, by fusion of single-chain variable fragments (scFv) of a TfR antibody with either a full-size IgG antibody of Aβ or tau or with their respective scFv. Using [18F]SFB as the prosthetic group, all four 18F-labeled bispecific antibody probes were then prepared by conjugation of antibody and [18F]SFB in acetonitrile/0.1 M borate buffer solution (final pH ~ 8.5) with an incubation of 20 min at room temperature, followed by purification on a PD MiniTrap G-25 size exclusion gravity column. Results: Based on both in vitro and ex vivo evaluation, the bispecific antibodies displayed much higher brain concentrations than the unmodified antibody, supporting our subsequent F18-radiolabeling. [18F]SFB was produced in high yields in 60 min (decay-corrected radiochemical yield (RCY) 46.7 ± 5.4) with radiochemical purities of >95%, confirmed by analytical high performance liquid chromatography (HPLC) and radio-TLC. Conjugation of [18F]SFB and bispecific antibodies showed a 65%-83% conversion efficiency with radiochemical purities of 95%-99% by radio-TLC. Conclusions: We successfully labeled four novel and specifically engineered bispecific antibodies with [18F]SFB under mild conditions with a high RCY and purities. This study provides strategies to create brain-penetrable F-18 radiolabeled antibody probes for the selective detection of tau and Aβ aggregates in the brain of transgenic AD mice via in vivo PET imaging.

Carbon-11 labeled stilbene derivatives from natural products for the imaging of Aβ plaques in the brain

68Ga-Labeled Benzothiazole Derivatives for Imaging Aβ Plaques in Cerebral Amyloid Angiopathy

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Novel Anilinophthalimide Derivatives As Potential Probes for Beta-Amyloid Plaque in the Brain

Synthesis and Radioiodinelabeling of β-Amyloid Plaques Imaging Agent 3'-~(131)I-PIB

Modified Auto-synthesis and Clinical Trial of the 11C-PIB as a Potential β-amyloid Imaging Agent

Synthesis and Biological Evaluation of ~(11)C-DPOD for PET Imaging Agent of Amyloid-b in Mouse Brain

Radiosynthesis and evaluation of acetamidobenzoxazolone based radioligand [C-11]N '-MPB for visualization of 18 kDa TSPO in brain

preparation of amyloid-beta imaging agent 11C-6-OH-BTA-1

Novel Indanone Derivatives As Potential Imaging Probes for Β‐amyloid Plaques in the Brain

Novel pyrrolidine-alkylamino-substituted dicyanoisophorone derivatives as near-infrared fluorescence probe for imaging β-amyloid in vitro and in vivo

Synthesis, radiolabeling, and evaluation of a potent β-site APP cleaving enzyme (BACE1) inhibitor for PET imaging of BACE1 in vivo

6-Methoxy-indanone Derivatives As Potential Probes for Β-Amyloid Plaques in Alzheimer's Disease

Naphthofuran Derivatives As Potential Imaging Agents for Β-Amyloid Plaques in the Brain

Synthesis and preclinical evaluation of diarylamine derivative as Tau-PET radiotracer for Alzheimer's Disease

Design, Synthesis and Biological Evaluation of 1,4-Diazobicylco[3.2.2]nonane Derivatives As Α7-Nicotinic Acetylcholine Receptor PET/CT Imaging Agents and Agonists for Alzheimer's Disease.

N-methylbenzothiazolium based theranostics as fluorescence imaging and photo-oxidation agents for Amyloid-β

Benzothiazolium Derivative-Capped Silica Nanocomposites for β-Amyloid Imaging In Vivo

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau

Imaging Brain Amyloid of Alzheimer Disease in Vivo in Transgenic Mice with an Aβ Peptide Radiopharmaceutical

Radiosynthesis and In-Vivo Evaluation of [125I]IBT